What
is SAM-e?
Sam-e,
or S-Adenosylmethionine, is a substance synthesized
from methionine (an amino acid) in the body. Children have seven
times more SAM-e than adults. Men have higher quantities of Sam-e
than women. Depression is linked to low SAM-e levels in people of
all ages. People suffering from Alzheimer’s also show lower
levels of SAM-e. An exogenous (produced outside of the body) form
of SAM-e was developed in the mid-seventies.
What
Does SAMe Actually Do?
SAM-e
is a “methyl donor”, playing a key role in the methylation
process in the body. Methylation is a basic chemical reaction that
triggers many vital biological responses throughout the body. SAM-e,
as a methyl donor, donates methyl groups to different molecules.
SAM-e helps methylate DNA, protein, and phospholipids. Sam-e, through
a process called transulferation, helps the body’s cells produce
glutathione, an essential compound for the immune system, and the
liver, where it helps in the important job of detoxification.
How
Can SAMe Help Me/My Family?
As
a Methyl donor, Sam-e plays a vital role in the production of norepinephrine
and seratonin, neurotransmitters important in regulating mood. Sam-e
also helps in the methylation of phospholipids helping to keep cell
membranes receptive to neurotransmitters. Sam-e can also boost the
production of phosphotidylserine, a phospholipid that plays a role
in memory and mood.
SAMe
and Osteoarthritis & Joint Health
In
studies Sam-e was shown to increase the production of chrondrocytes,
the cartilage producing cells in joints. Proteoglycans, molecules
important to the lubrication of joints, appear to remain stable,
maintaining their effectiveness, with the help of SAMe. SAMe has
been featured in "SAMe: The European Arthritis And Depression
Breakthrough" by Dr. Sol Grazi.
SAMe
and the Liver
As
stated earlier, SAMe helps the body produce glutathione an important
substance to the chemical processes of the liver. Glutathione helps
the liver detoxify alcohol, drugs, and poisons such as insecticides.
Glutathione helps make toxic substances water-soluble allowing these
substances to be cleansed from the system.
LifeSource Nutrition considers SAMe an excellent product with great
potential if taken properly as described by your doctor.
Current
Research on SAMe:
The
U.S. Department of Health and Human Services’ (HHS) Agency
for Healthcare Research and Quality (AHRQ) conducted an extensive
literature review to determine SAM-e’s efficacy for treatment
of depression, osteoarthritis, and cholestasis of pregnancy and
intrahepatic cholestasis associated with liver disease. The results
were released in late 2002 and summarized below, along with other
data.
Depression:
Depression will affect 10 to 25 percent of women and 5 to 12 percent
of men in the United States. Approximately 10 to 15 million people
experience clinical depression in any given year. The antidepressant
effects of SAMe administration were first documented in 1974. Further
research in depressive disorders was reviewed in 1988, 1989, 1994,
2000, and 2002.
The
AHRQ included 28 studies in a meta-analysis of the efficacy of SAMe
to decrease symptoms of depression. Compared to placebo, SAMe was
associated both statistically and clinically with significant improvements
in the score of the Hamilton Rating Scale for Depression. When compared
to conventional antidepressants, treatment with SAMe was not associated
with a statistically significant difference in outcomes suggesting
SAMe is as effective as most antidepressant prescription drugs.
A
2002 review concluded that treatment with parenteral or oral SAMe
at doses of 200-1600 mg/day was superior to placebo and as effective
as tricyclic antidepressants with a faster onset of action.
Two
multi-center studies were conducted on patients to confirm the efficacy
and safety of SAMe in the treatment of major depression. The first
study group received 1600 mg/day of SAMe orally, while the second
study group received 400 mg/day SAMe intramuscularly. Both studies
compared SAMe to 150 mg a day in a double-blind design. The study
concluded the anti-depressive effectiveness of both oral and intramuscular
SAMe was comparable to 150-mg imipramine/day. In addition, SAMe
had fewer adverse events and was significantly better tolerated.
SAMe
has been studied in 16 open uncontrolled trials with a total of
660 patients; 13 randomized, double blind, placebo-controlled trials
with 537 patients; 19 controlled trials of SAMe verses other antidepressants
involving 1134 patients. SAMe consistently showed significant anti-depressive
effects in all 16 open trials and outperformed placebo in all controlled
trials with exception of one. In 18 controlled trials, SAMe was
as effective as imipramine, chlorimipramine, amytriptyline, nomifensine
and minaprine and caused fewer side effects. The rapid onset of
action (5-10 days) was noted in 7 of the depression studies.
Arthritis:
There are more than 100 different types of arthritis, ranging from
mild tendinitis to severe forms such as osteoarthritis (OA), the
most common form of arthritis. Arthritis is often categorized by
symptoms such as inflammation, redness, heat and pain. An estimated
15 percent of Americans suffer from arthritis, and the annual cost
to society is estimated at 95 billion. Standard treatment therapies
for osteoarthritis include non-steroidal anti-inflammatory medication,
non-pharmacologics (e.g. exercise, heat treatment) and surgery.
Because of side effects from pharmacologic agents, SAMe was studied
for its effects on reducing the pain associated with OA. Out of
13 unique studies considered in the ARHQ study, 10 studies were
included in a meta-analysis of the efficacy of SAMe to decrease
pain of osteoarthritis.
One
large randomized clinical trial showed an effect size in favor of
SAMe of 0.20 (95 percent CI [-0.39, - 0.02]) compared to placebo,
thus demonstrating a decrease in the pain of osteoarthritis.
Compared
to treatment with non-steroidal anti-inflammatory medication, treatment
with SAMe was not associated with a statistically significant difference
in outcomes (effect size 0.11; 95 percent CI [0.56, 0.35]).
In
November 1987, the American Journal of Medicine published 20 papers
from a symposium on SAMe and arthritis including 9 clinical trials
with more than 22,000 participants. These studies, as well as others,
indicate that SAMe exerts anti-inflammatory and analgesic effects
equivalent to those of several prescription, nonsteroidal, anti-inflammatory
drugs, but that it does not cause gastrointestinal bleeding. Anti-inflammatory
effects require 3 to 4 weeks of treatment (200-400 mg orally every
day) in mild to moderate cases.
Liver
Disease: Abnormal SAMe synthesis is associated with liver
disease, regardless of the etiology. Loss of activity in the enzyme
methionine adenosyltransferase (MAT) results in decreased concentrations
of SAMe and depletion of glutathione. The loss of glutathione further
impairs SAMe production because glutathione is needed to stabilize
MAT and to protect the enzyme from free radical damage.
The
AHRQ included 6 studies in a meta-analysis of the efficacy of SAMe
to relieve pruritus and decrease elevated bilirubin levels associated
with intrahepatic cholestasis caused by a variety of liver diseases.
Patients treated with SAMe were twice as likely as placebo-treated
patients to have a reduction in pruritus.
The
AHRQ included 8 studies in a meta-analysis of the efficacy of SAMe
to relieve pruritus and decrease elevated serum bilirubin levels
associated with cholestasis of pregnancy. Compared to placebo, treatment
with SAMe for cholestasis of pregnancy was associated with a decrease
in pruritus and bilirubin levels.
A
review of 17 clinical trials shows that SAMe improved symptoms and
biochemical markers (serum bilirubin, alkaline phosphatase, gamma-glutamyl
transpeptidase, transaminases, cysteine, taurine, and hepatic glutathione)
of liver diseases, including alcoholic and nonalcoholic hepatitis
and cirrhosis, oral-contraceptive-induced cholestasis, other forms
of cholestasis, and metabolic disorders of porphyrin and bilirubin.
Bottom
Line: SAMe is a very safe supplement and a great way to
stop disease’s mentioned above by taking lower doses as a
preventative as well as fighting the current diseases that you may
have by taking a little larger doses.
| Supplement
Facts |
MG |
%DV |
| |
|
|
| Serving
Size: 1 capsule |
|
|
| Servings
per: 30 |
|
|
| |
|
|
| Vitamin
B-6 (as Pyridoxine HCI) |
2
mg. |
100%
|
| Viamin
B-12 (as Cyanocobalamin) |
50
mcg. |
833%
|
| Folic
Acid |
200
mcg. |
50%
|
| SAMe
(S-Adenosyl-L-Methlonine) |
200
mg. |
*
|
|